Learn about CC chemokine receptor 8, its role in cancer, and how BMS researchers investigate antibody-mediated Treg depletion targeting CCR8 as an immunotherapy mechanism.

Mar 23, 2021 · CC chemokine receptor 8 (CCR8) is a protein found mainly on the surface of a highly immunosuppressive subset of regulatory T cells (Tregs) within tumors. It is a regulator of immune response.1,2. Receptors like CCR8 and their chemokines play an important role in the immune system’s response to cancer.

A human immunoglobulin G1 (IgG1) nonfucosylated (NF) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities.

Aug 15, 2020 · BMS-986340 (anti-CCR8 hIgG1-nonfucosylated [NF] antibody) was developed and used for CCR8+ Treg depletion in human tumor explants. Results: CCR8 gene expression had the highest correlation with FOXP3 in most cancer types in TCGA.

Apr 18, 2024 · CCR8, which stands for C-C chemokine receptor type 8, belongs to the GPCR family, and is known to be expressed on the surface of T regulatory cells. As Tregs have an immunosuppressive function their downregulation, for instance by blocking CCR8, could boost immune system activity.

To generate an anti-human CCR8 antibody suitable for cancer immunotherapy, we screened monoclonal anti-CCR8 IgG1 antibodies and found a novel anti-human CCR8 antibody S-531011 that showed high binding affinity to CCR8, ADCC activity, and neutralization activity against CCR8-mediated signaling.

Feb 1, 2025 · Recent studies demonstrate that CC chemokine receptor (CCR)8 is highly and specifically expressed on effector TI-Treg cells in mice and humans, highlighting CCR8 as a promising target for selective TI-Treg cell depletion in the treatment of various cancers.

Jun 1, 2021 · Preclinical mouse tumor modeling showed that depletion of CCR8 + Tregs through an FcyR-engaging anti-CCR8 antibody, but not blockade, enabled dose-dependent, effective, and long-lasting antitumor immunity that synergized with PD-1 blockade.

Reconstitute lyophilized powder with water to a concentration of 100 ug/ml, solubilize at RT for 30 minutes with occasional gentle tapping. It is recommended that 0.1% HSA be added as a carrier protein for long-term storage. Shipped at ambient conditions. Lyophilized form is stable for 1 week at room temperature.

Jan 18, 2025 · Upon administration, anti-CCR8 monoclonal antibody BMS-986340 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 …